In addition, we proposed the conclusion in our study that PLD1 inhibition might be an alternative approach for the management of glioma based solely on the data in vitro without any data on vivo. Furthermore, our study did not give the detailed mechanisms whereby PLD1 interacts with CyclinD1, CDK4 and MMP9. This evidence concerns the gene MMP9 and central nervous system cancer.